Pricing and Market Access Considerations for Cell and Gene In the past two years, four cell and gene therapies have entered the U.S. market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million for a one-time treatment. Payers view these new therapies as having moderate to high clinical value but have significant concerns around long term durability of effect. For example, will [...]
A potential payer solution for Cell & Gene Therapies A US and European perspective Payer concerns over increasing cost of therapies and uncertainty of clinical data have led to a growing interest in market access tools. These tools have many names and definitions, often referred to as innovative (IAA) or alternative access agreements (AAA). For the purpose of this review we will refer to them collectively as IAA. The [...]
Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents. However, new ways to control the cost of oncology care are emerging [...]
Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome. To further complicate the category, indications can be subdivided even further (e.g., by severity, juvenile vs. adult, etc.), increasing the complexity even more.
This has been an exciting week for gene therapy in the U.S. market. With the approval of Novartis’ novel CAR-T gene therapy, and a launch price below analyst expectations, there is uncertainty around the pricing expectations for future pipeline agents. How will payers pay for these new gene therapies? Did Novartis set the price reference for Juno’s and Gilead/Kite’s CAR-T entrants?
With recent disruptive pricing in the HCV market, will lower cost therapies take share from legacy treatments? Preview what payers forecast back in the second half of 2016 with our M Tracker data. Will their prediction become reality? Be on the lookout for the full report in the near future!
With the evolution of payer management in different specialty classes, MKO has been tracking management priority and budget impact using our M Tracker. M Tracker has revealed a significant change in oncology and HCV management in the first half of 2017. Here is a preview of current payer opinions on specialty disease management, using our proprietary M Tracker data. Click HERE to see the animation [...]
At Two Labs, we value partnership. We work hard to make sure our clients view us as an extended part of their team, and not just another vendor. As the pharma market continues to evolve, we are excited to expand our team so that we can provide even more value to our clients as they navigate the path of bringing their products to market.
Two of the biggest pharmaceutical companies, Pfizer Inc. and GlaxoSmithKline, are significantly reducing spending with doctors for events at which doctors make presentations to their peers. Combined with cutbacks in spending on meals during lunchtime presentations by drug makers, doctors are feeling the financial impact. Increased Scrutiny of Pharmaceutical Marketing Practices - Will it Affect Drug Development? Pfizer and GlaxoSmithKline have cut spending on dinners and other events where expert doctors are [...]
Overview: Both the FDA and the EMA are showing increasing levels of support for biosimilars, while physician resistance is declining in both the US and Europe. Cost is a big driver, among other factors. Biosimilar Drug Development Trends in Europe – Timing is Everything Resistance to biosimilars in Europe is declining just as patents are expiring on many highly lucrative biologics, among them Herceptin (trastuzumab), Remicade (infliximab), and Rituxan(rituximab). Significant cost advantages, important regulatory changes, [...]